Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —
— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —